血浆循环肿瘤DNA作为头颈癌疾病监测的潜在工具
研究纳入8例头颈鳞状细胞癌患者,对肿瘤测序鉴定患者特异性突变,并在治疗前及标准随访期间纵向检测血浆循环肿瘤DNA,分析其与疾病复发的关系。7例验证到肿瘤突变,6例基线循环肿瘤DNA阳性,4例复发其中2例在复发前可检测到循环肿瘤DNA。循环肿瘤DNA是头颈癌根治性治疗后疾病和复发监测的潜在工具。
要点
- 8例头颈鳞状细胞癌患者中7例验证到肿瘤突变,6例基线循环肿瘤DNA阳性。
- 4例复发患者中2例在复发前可检测到循环肿瘤DNA。
- 循环肿瘤DNA是头颈癌根治性治疗后疾病和复发监测的潜在工具。
核心结论
- 循环肿瘤DNA是头颈癌根治性治疗后疾病和复发监测的潜在工具,有助于更好地判断预后和/或调整治疗策略。
研究设计与样本
- 研究招募诊断为头颈鳞状细胞癌的患者进入研究方案,对肿瘤测序以鉴定患者特异性突变,并在治疗前血液样本及标准随访期间纵向检测血浆循环肿瘤DNA中的突变。
主要发现
- 样本取自8例患者,其中7例验证到肿瘤突变。
- 6例患者基线循环肿瘤DNA阳性。
- 4例患者发生复发,其中2例在复发前可检测到循环肿瘤DNA。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recommendations for perioperative therapy in head and neck cancer are not explicit and recurrence occurs frequently. Circulating tumor DNA is an emerging cancer biomarker, but has not been extensively explored for detection of recurrence in head and neck cancer. METHODS: Patients diagnosed with head and neck squamous cell carcinoma were recruited into the study protocol. Tumors were sequenced to identify patient-specific mutations. Mutations were then identified in plasma circulating tumor DNA from pre-treatment blood samples and longitudinally during standard follow-up. Circulating tumor DNA status during follow-up was correlated to disease recurrence. RESULTS: Samples were taken from eight patients. Tumor mutations were verified in seven patients. Baseline circulating tumor DNA was positive in six patients. Recurrence occurred in four patients, two of whom had detectable circulating tumor DNA prior to recurrence. CONCLUSION: Circulating tumor DNA is a potential tool for disease and recurrence monitoring following curative therapy in head and neck cancer, allowing for better prognostication, and/or modification of treatment strategies.
引用
- Egyud M, Sridhar P, Devaiah A, et al. Plasma circulating tumor DNA as a potential tool for disease monitoring in head and neck cancer. Head Neck. 2018. PMID: 30554450. doi:10.1002/hed.25563
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。